Thematic Poster
Common mechanisms in lung development and fibrosis
A role for the accessory type III transforming growth factor β receptor (Tgfbr3) in lung alveolarisation
A. Pozarska(Gießen, Germany)
COI
1
Refinement of the hyperoxia-based experimental mouse model of bronchopulmonary dysplasia
C. Nardiello(Bad Nauheim, Germany)
COI
2
Optimising the delivery of antagomiRs to the neonatal mouse lung
J. Hönig(Bad Nauheim, Germany)
COI
3
Assessing the impact of parenteral caffeine administration on experimental bronchopulmonary dysplasia
P. Rath(Bad Nauheim, Germany)
COI
4
Generation of an immortalized functional alveolar epithelial cell line originating from human induced pluripotent stem cells
A. Gazdhar(Schliern b. Köniz, Switzerland)
COI
5
LSC Abstract – Activation of FGF9 and 18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts
A. Joannes(RENNES, France)
COI
6
Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model
K. Nishikawa(Yamaguchi, Japan)
COI
7
Fibroblast growth factor 9 (FGF9) modulates mesothelial cells plasticity to decrease differentiation and migration in vitro
A. Joannes(RENNES, France)
COI
8
MiRNA-200b inhibits epithelial-mesenchymal transition in TGF-β1 induced human bronchial epithelial cells
S. Ladak(Newcastle upon Tyne (Tyne and Wear), United Kingdom)
COI
9
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
J. Roberts(Southampton (Hampshire), United Kingdom)
COI
10
The effects of tobramycin on pulmonary fibroblast function
S. Edgar(Portsmouth (Hampshire), United Kingdom)
COI
11
Human airway trypsin-like protease: Friend or foe in idiopathic pulmonary fibrosis?
A. Gasnier Menou(Nantes, France)
COI
12
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
K. Nemoto(Ibaraki, Japan)
COI
13
Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF)
F. Conforti(Southampton (Hampshire), United Kingdom)
COI
14
Prostacyclin and VEGF in the rejection process after lung transplantation – A possible biomarker
A. Andersson Sjoland(Lund, Sweden)
COI
15
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
M. Dubourdeau(Toulouse, France)
COI
16
LATE-BREAKING ABSTRACT: Morphology and molecular basis of damage stem cell niche respiratory acini (SCNRA) in idiopathic interstitial pneumonia (IIP)
E. Kogan(Moscow, Russian Federation)
COI
17
LATE-BREAKING ABSTRACT: Interfacial sensing a new regulator of pulmonary epithelial barrier function
D. Korejwo(Innsbruck, Austria)
COI
18
LATE-BREAKING ABSTRACT: KCa3.1 ion channel-blockade reduces pulmonary fibrotic responses via the inhibition of fibroblast proliferation
L. Organ(Nottingham (Nottinghamshire), United Kingdom)
COI
19
LSC Abstract - Differentiation between inflammation and hyperinflammation in the murine lung
K. Reiss(Aachen, Germany)
COI
20
. . .
